Bicara Therapeutics (BCAX) Other Operating Expenses (2023 - 2026)
Bicara Therapeutics (BCAX) posted quarterly Other Operating Expenses of $47.4 million for Q1 2026, up 70.76% year-over-year from $27.8 million in Q1 2025, and down 62.11% quarter-over-quarter from $125.1 million in Q4 2025.
Bicara Therapeutics (BCAX) Other Operating Expenses (2023 - 2026) Analysis & Trends
Bicara Therapeutics' Other Operating Expenses history runs 4 years deep, the most recent figure standing at $47.4 million for Q1 2026.
- In Q1 2026, Other Operating Expenses rose 70.76% year-over-year to $47.4 million; the TTM figure through Mar 2026 stood at $172.5 million (up 107.46% YoY), while the FY2025 annual figure was $125.1 million, up 125.79% from the prior year.
- Other Operating Expenses for Q1 2026 stood at $47.4 million, down from $125.1 million in the prior quarter.
- The five-year high for Other Operating Expenses was $125.1 million in Q4 2025, with the low at -$36000.0 in Q3 2024.
- The 4-year median for Other Operating Expenses is $41000.0 (2024), against an average of $23.2 million.
- Peak annual rise in Other Operating Expenses reached 89201.61% in 2024, while the deepest fall reached 192.31% in 2024.
- Bicara Therapeutics' Other Operating Expenses stood at $62000.0 in 2023, then surged by 89201.61% to $55.4 million in 2024, then jumped by 125.93% to $125.1 million in 2025, then slumped by 62.11% to $47.4 million in 2026.
- Business Quant data shows BCAX's Other Operating Expenses at $47.4 million in Q1 2026, $125.1 million in Q4 2025, and -$25000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Bicara Therapeutics | 1.60 Bn | 1.60 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 47.40 Mn |
| Dec 31, 2025 | 125.09 Mn |
| Sep 30, 2025 | -25,000.00 |
| Jun 30, 2025 | -2,000.00 |
| Mar 31, 2025 | 27.76 Mn |
| Dec 31, 2024 | 55.37 Mn |
| Sep 30, 2024 | -36,000.00 |
| Jun 30, 2024 | 41,000.00 |
| Mar 31, 2024 | 32,000.00 |
| Dec 31, 2023 | 62,000.00 |
| Sep 30, 2023 | 39,000.00 |